罗沙司他辅助促红细胞生成素对肾性贫血患者疗效及对转铁蛋白、转铁蛋白饱和度的影响  

Effect of roxallistat assisted erythropoietin on renal anemia patients and its effect on transferrin and transferrin saturation

作　　者：杨永彪 丁广贵 何猛 钟颉 吴雪平[2] YANG Yongbiao;DING Guanggui;HE Meng;ZHONG Jie;WU Xueping(Department of Nephrology,Mingguang People's Hospital,Chuzhou 239400,Anhui Province,China;Department of Nephrology,the First Affiliated Hospital of Bengbu Medical College,Bengbu 233004,Anhui Province,China)

机构地区：[1]明光市人民医院肾病医学科,安徽滁州239400 [2]蚌埠医学院第一附属医院肾病科,安徽蚌埠233004

出　　处：《世界临床药物》2024年第9期957-961,共5页World Clinical Drug

摘　　要：目的 探讨罗沙司他辅助促红细胞生成素(erythropoietin,EPO)对肾性贫血(renal anemia,RA)患者的疗效及对转铁蛋白(transferrin,TRF)、TRF饱和度(transferrin saturation,TSAT)等的影响。方法 选择2021年1月至2023年12月明光市人民医院肾病医学科接受治疗的RA患者179例,以随机数表法分为试验组(n=90,EPO+罗沙司他)和对照组(n=89,EPO),两组均治疗12个月。比较两组临床疗效、TRF、TSAT、贫血指标[红细胞(red blood cell,RBC)、血红蛋白(hemoglobin,Hb)、血清铁蛋白(serum ferritin,SF)]水平及不良反应发生情况。结果 治疗后,试验组临床有效率高于对照组(91.11% vs 79.78%,P<0.05)。两组TRF、TSAT、RBC、Hb、SF水平较前均升高(P<0.05),且试验组高于对照组(P<0.05)。试验组及对照组不良反应发生率分别为6.67%、10.11%,无明显差异(P>0.05)。结论 罗沙司他辅助EPO治疗RA效果较佳,改善TRF、TSAT水平及贫血情况良好。Objective To investigate the effect of roxallistat assisted erythropoietin(EPO)on patients with renal anemia(RA)and its effect on transferrin(TRF)and TRF saturation(TSAT)levels.Methods A total of 179 RA patients treated in the department of nephrology,Mingguang people's hospital from January 2021 to December 2023 were selected and divided into experimental group(n=90,EPO+roxallistat)and control group(n=89,EPO)by random number table method.Both groups were treated for 12 months.The clinical efficacy,TRF,TSAT,serum indexes of anemia[red blood cell(RBC),hemoglobin(Hb),serum ferritin(SF)]and the incidence of adverse reactions were compared between the two groups.Results After treatment,the clinical effective rate of experimental group was higher than that of control group(91.11%vs 79.78%,P<0.05).The levels of TRF,TSAT,RBC,Hb and SF in both groups were higher than before(P<0.05),and the experimental group was higher than the control group(P<0.05).The incidence of adverse reactions in experimental group and control group was 6.67%and 10.11%,respectively,with no significant difference(P>0.05).Conclusion Roxallistat assisted EPO in the treatment of RA is effective,and can improve the level of TRF,TSAT and anemia.

关 键 词：罗沙司他 促红细胞生成素 肾性贫血 转铁蛋白 转铁蛋白饱和度 

分 类 号：R692.5[医药卫生—泌尿科学]